KNSA - Kiniksa Pharmaceuticals, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development85,66255,95517,153
Selling General and Administrative22,4989,4456,849
Non Recurring---
Total Operating Expenses108,16065,40024,002
Operating Income or Loss-108,160-65,400-24,002
Income from Continuing Operations
Total Other Income/Expenses Net4,71952965
Earnings Before Interest and Taxes-108,160-65,400-24,002
Interest Expense---
Income Before Tax-103,441-64,871-23,937
Income Tax Expense-214236
Minority Interest---
Net Income From Continuing Ops-103,227-64,873-23,973
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-103,227-64,873-23,973
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-103,227-64,873-23,973